Status:
COMPLETED
Study on Safety and Effectiveness of Ergoferon in the Treatment of Flu / ARVI in Outpatients.
Lead Sponsor:
Materia Medica Holding
Conditions:
Viral Respiratory Infection
Eligibility:
All Genders
6-75 years
Brief Summary
The observational study to get the additional data of the safety and effectiveness of Ergoferon in the treatment of influenza/ARVI in adult and pediatric outpatients.
Detailed Description
This observational study is aimed to provide additional safety and effectiveness data for Ergoferon in the treatment of influenza/ARVI in adult and pediatric outpatients, including cases with delayed ...
Eligibility Criteria
Inclusion
- Data of children from 6 months to 18 years old and adults over 18 years old.
- Diagnosis: Flu / ARVI.
- Axillary temperature above 37.4 °С.
- At least one systemic and/or catarrhal symptom lasting 12 hours to 3 days by the time the doctor is consulted, for which treatment with Ergoferon is prescribed.
- A specific decision of the doctor to prescribe Ergoferon in strict accordance with the indications, regardless of the factor of including patient data in the program.
- CRF, filled by a doctor on the basis of medical documentation, at the end of patient observation.
Exclusion
- Not applicable.
Key Trial Info
Start Date :
October 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
8411 Patients enrolled
Trial Details
Trial ID
NCT04413929
Start Date
October 1 2016
End Date
April 1 2017
Last Update
April 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.